Plain-English translation of NCT06958016 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand whether a blood protein called tryptase can help predict when patients with stable coronary artery disease (gradual narrowing of heart vessels) might suddenly become worse. By studying tryptase levels in patients with and without significant heart vessel narrowing, this study aims to find a simple blood test that could warn doctors about future heart problems.
Patients with stable heart vessel disease can sometimes experience sudden, life-threatening changes without warning. This medication aims to identify a blood marker that could predict these dangerous shifts early, allowing doctors to intervene before serious complications occur.
You likely qualify if…
You likely don't qualify if…
You will visit the research center for a heart catheterization procedure (a standard test where doctors examine your heart vessels). Blood samples will be collected during this visit to measure tryptase and other markers. The study compares tryptase levels between patients with significant heart vessel narrowing and those without, to see if this blood protein can predict future complications.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Greece
Sponsor
University of Thessaly
Enrollment target
~200 participants
Started
January 2024
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fotios Skoufis, MD Medicine
University of Thessaly
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.